New England Capital Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

New England Capital Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-200	Closed	-$176K	–	413
2023 Q4	$176K	Hold	200	–	–	0.11%	55
2023 Q3	$165K	Hold	200	–	–	0.11%	56
2023 Q2	$144K	Hold	200	–	–	0.09%	59
2023 Q1	$164K	Hold	200	–	–	0.12%	58
2022 Q4	$144K	Buy	+200	New	+$148K	0.1%	59

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

New England Capital Financial Advisors's REGN Position: Q1 2024 in Review

New England Capital Financial Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 200 shares — an estimated $176K sold.

New England Capital Financial Advisors first reported a position in REGN in Q4 2022 and held it in 5 quarters. The position peaked at $176K in Q4 2023. 1,310 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

New England Capital Financial Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
New England Capital Financial Advisors sold 200 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $176K.
New England Capital Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 5 quarters.
New England Capital Financial Advisors's Regeneron Pharmaceuticals position peaked at $176K in Q4 2023.
1,310 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on New England Capital Financial Advisors's 13F filing for Q1 2024, filed 2 May 2024.